Results 21 to 30 of about 38,820 (264)

The effect of SRIH-14 or octreotide on the morphological characteristics of adrenal medulla using newcast [PDF]

Archives of Biological Sciences, 2010
The effects of chronic treatments with either SRIH-14 or octreotide on the adrenal medulla of male Wistar rats were examined. Adult males received subcutaneous (s.c.) injections of 20 μg/100 g body weight of either SRIH-14 or octreotide twice a day for ...
Trifunović Svetlana, Filipović B., Ajdžanović V., Manojlović-Stojanoski Milica, Nestorović Nataša, Sekulić Milka, Milošević Verica   +6 more
doaj   +1 more source

Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial

Trials, 2011
Background Polycystic liver disease (PLD) is defined as having more than 20 liver cysts and can present as a severe and disabling condition. Most symptoms are caused by the mass effect of the liver size and include abdominal pain and distension.
Chrispijn Melissa, Drenth Joost PH
doaj   +1 more source

The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells. [PDF]

PLoS ONE, 2012
Octreotide is a widely used synthetic somatostatin analogue that significantly improves the management of neuroendocrine tumours (NETs). Octreotide acts through somatostatin receptors (SSTRs).
Su-Chen Li, Cécile Martijn, Tao Cui, Ahmed Essaghir, Raúl M Luque, Jean-Baptiste Demoulin, Justo P Castaño, Kjell Öberg, Valeria Giandomenico   +8 more
doaj   +1 more source

ANNIVERSARY REVIEW: Octreotide, 40 years later.

European Journal of Endocrinology, 2019
Octreotide remains 40 years after its development a drug, which is commonly used in the treatment of acromegaly and GEP-NETs. Very little innovation that competes with this drug occurred over this period. This review discusses several aspects of 40 years
S. Lamberts, L. Hofland
semanticscholar   +1 more source

The effect of preoperative short-term octreotide treatment to surgery in thyrotropin-secreting pituitary adenomas: a retrospective cohort study

BMC Endocrine Disorders, 2023
Background To prevent thyroid storm and ensure surgical safety, it is imperative to regulate excessive thyroid hormone levels in patients with thyrotropin-secreting pituitary adenomas (TSHoma) prior to surgery.
Runsheng Zhao, Kaiyu Fan, Weiqing Wan
doaj   +1 more source

Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518.

Journal of Clinical Oncology, 2017
Purpose Treatment options for neuroendocrine tumors (NETs) remain limited. This trial assessed the progression-free survival (PFS) of bevacizumab or interferon alfa-2b (IFN-α-2b) added to octreotide among patients with advanced NETs. Patients and Methods
James C. Yao, K. Guthrie, C. Moran, J. Strosberg, M. Kulke, J. Chan, N. Loconte, R. McWilliams, E. Wolin, B. Mattar, Shannon L. McDonough, Helen X. Chen, C. Blanke, H. Hochster   +13 more
semanticscholar   +1 more source

Octreotide in Intestinal Lymphangiectasia: Lack of a Clinical Response and Failure to Alter Lymphatic Function in a Guinea Pig Model

Canadian Journal of Gastroenterology, 2004
Intestinal lymphangiectasia, which can be classified as primary or secondary, is an unusual cause of protein-losing enteropathy. The main clinical features include edema, fat malabsorption, lymphopenia and hypoalbuminemia.
S Makhija, P-Y vod der Weid, J Meddings, SJ Urbanski, PL Beck   +4 more
doaj   +1 more source

Influência do octreotide subcutâneo na cicatrização de sutura gástrica em ratos Effect of octreotide administered subcutaneously on the healing of gastric sutures in rats

ABCD: Arquivos Brasileiros de Cirurgia Digestiva, 2007
RACIONAL: Octreotide, análogo sintético da somatostatina, é potente inibidor da secreção gástrica, intestinal e pancreática. Reduz fluxo sangüíneo esplâncnico, acelera esvaziamento gástrico e prolonga tempo de trânsito intestinal, estimulando a absorção ...
Paula Suzin Trubian, Alessandra Borges Branco, Antonio Carlos Ligocki Campos, Marcelo Ferreira, Patrícia Suzin Trubian, Jorge Eduardo Fouto Matias   +5 more
doaj   +1 more source

Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial

PLoS Medicine, 2019
Background Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent genetically determined renal disease. In affected patients, renal function may progressively decline up to end-stage renal disease (ESRD), and approximately 10% of those
N. Perico, P. Ruggenenti, A. Perna, Anna Caroli, Matias Trillini, Sandro Sironi, Antonio Pisani, E. Riccio, Massimo Imbriaco, M. Dugo, Giovanni Morana, Antonio Granata, M. Figuera, F. Gaspari, Fabiola Carrara, N. Rubis, Alessandro Villa, Sara Gamba, Silvia Prandini, Monica Cortinovis, A. Remuzzi, Giuseppe Remuzzi   +21 more
semanticscholar   +1 more source

Octreotide-induced thrombocytopenia: a case report

Journal of Medical Case Reports, 2011
Introduction Thrombocytopenia is an extremely rare complication of octreotide therapy and can be life threatening in the setting of esophageal variceal bleeding.
Rizvi Nahid, Rashidi Armin
doaj   +1 more source